TP53 and central nervous system cancer: On the other hand, because TP53, ATRX and IDH mutations are early events in gliomas [23], protein expression assessed by IHC is either diffusely lost (ATRX) or diffusely present (protein IDH1 R132H, p53) in tumor cells (Figure 5).